Short answer
Coherus Oncology, Inc. (CHRS) filed an 8-K current report with the SEC on August 28, 2026 reporting Item 8.01 (Other Events). At-the-market equity facility enabling up to $50.0 million in common-stock sales.
Coherus Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- At-the-market equity facility enabling up to $50.0 million in common-stock sales
- No obligation to issue shares, preserving financing flexibility but creating potential dilution
- Leerink Partners commission up to 3.0% of gross proceeds
- Proceeds designated for general corporate purposes, including working capital
- Sales Agreement terminable by either party with 10 days’ notice
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Coherus Oncology, Inc. 8-K filings
Get the next CHRS 8-K as it lands
Follow CHRS for push alerts, or ask the research agent what this filing means.